---
schema_version: "secwatch.filing_event.v1"
accession: "0000929638-26-001834"
form_type: "8-K"
ticker: "CTSO"
cik: "0001175151"
company_name: "Cytosorbents Corp"
filed_at: "2026-05-13T20:05:35+00:00"
generated_at: "2026-05-13T22:09:55.436213+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Q1 rev $8.9M (+2%); net loss $5.1M; DrugSorb-ATR FDA submission delayed to late 2026/early 2027

## Summary
- Revenue $8.9M, +2% YoY; gross margin 69% vs 71% in Q1 2025.
- Net loss $5.1M ($0.08/share) vs $1.5M ($0.02) in Q1 2025, driven by non-cash FX; adjusted net loss improved to $3.4M ($0.05).
- Cash $6.4M vs $7.8M Dec 31; cash burn $1.1M (excl. $0.3M restructuring); targeting operating cash flow breakeven H2 2026.
- DrugSorb-ATR for Brilinta: new De Novo submission delayed to late 2026/early 2027 after FDA requested additional mechanistic data.
- Distributor orders delayed ~$500k in Middle East due to U.S.-Iran war; Germany direct sales slightly down but with smaller team.

## SEC filing metadata
- accession: 0000929638-26-001834
- form_type: 8-K
- ticker: CTSO
- cik: 0001175151
- company_name: Cytosorbents Corp
- filed_at: 2026-05-13T20:05:35+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1175151/000092963826001834/0000929638-26-001834-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1175151/000092963826001834/a8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000929638-26-001834
- JSON: https://secwatch.observer/filing/0000929638-26-001834.json
- Plain text: https://secwatch.observer/filing/0000929638-26-001834.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.